Cargando…

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer

Detalles Bibliográficos
Autor principal:	Schmid, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Podcast
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212679/ https://www.ncbi.nlm.nih.gov/pubmed/30425847 http://dx.doi.org/10.1136/esmoopen-2018-000453

Ejemplares similares

ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE
por: Parker, Chris
Publicado: (2018)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

ESMO Open: news in breast cancer 2019
por: Lambertini, Matteo
Publicado: (2020)

ESMO Leaders Generation Programme: an alumni insight
por: Arruda, Leticia De Mattos, et al.
Publicado: (2018)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

ESMO20 YO for YO: highlights on oncogene-addicted NSCLC
por: Lim, K.H.J., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on upper GI tumours
por: Cardone, C., et al.
Publicado: (2020)

ESMO Open special series on new emerging targets in cancer immunotherapy
por: Lambertini, Matteo
Publicado: (2020)

ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
por: Matikas, A., et al.
Publicado: (2020)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
por: Emens, L.A., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update
por: Mariamidze, E., et al.
Publicado: (2021)

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
por: Lambertini, M., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma—the CheckMate-9ER trial
por: Kfoury, M., et al.
Publicado: (2021)

Highlights from the San Antonio Breast Cancer Symposium 2015
por: Jassem, Jacek
Publicado: (2016)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
por: Iwata, Hiroji, et al.
Publicado: (2019)

Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
por: Iwata, Hiroji, et al.
Publicado: (2020)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
por: De Giglio, Andrea, et al.
Publicado: (2019)

Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)
por: Saji, Shigehira, et al.
Publicado: (2022)

Highlights in breast cancer from ASCO 2016
por: Cardoso, Fatima
Publicado: (2016)

New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology
por: Senkus, Elżbieta
Publicado: (2017)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
por: Sharmni Vishnu, K., et al.
Publicado: (2022)

Introducing the Metastatic Breast Cancer Project: a novel patient-partnered initiative to accelerate understanding of MBC
por: Parry, Marina
Publicado: (2018)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

Tumour network in glioma
por: Winkler, Frank
Publicado: (2016)

ASCO highlights podcast: head and neck cancers
por: Merlano, Marco
Publicado: (2016)

Cancer genome: highlights of a Nature Medicine perspective
por: Voest, Emile
Publicado: (2016)

Recent advances in adjuvant therapy for patients with melanoma
por: Weber, Jeffrey
Publicado: (2018)

Immunotherapy in lung cancer
por: Vansteenkiste, Johan F
Publicado: (2018)

New therapeutic targets in the inflammatory microenvironment
por: Tartour, Eric
Publicado: (2018)

Questions asked in the everyday practice: immune checkpoint inhibitors
por: Haanen, John B A G
Publicado: (2018)

Macrophage repolarisation therapy in colorectal cancer
por: Halama, Niels
Publicado: (2018)

Epigenetic biomarkers in cancer
por: Egger, Gerda
Publicado: (2018)

Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer
por: Argiles, Guillem
Publicado: (2018)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer
por: Vansteenkiste, Johan F
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rfsrc1e9o3eo0g4523v804t1kr